Enlivex Therapeutics (NASDAQ:ENLV) Upgraded to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Enlivex Therapeutics (NASDAQ:ENLV) from a hold rating to a strong-buy rating in a report released on Tuesday,Zacks.com reports.

A number of other brokerages have also weighed in on ENLV. Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 25th. HC Wainwright upped their target price on Enlivex Therapeutics from $195.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $247.50.

Enlivex Therapeutics Price Performance

Shares of Enlivex Therapeutics stock opened at $4.59 on Tuesday. Enlivex Therapeutics has a 1-year low of $4.25 and a 1-year high of $31.50. The company has a market capitalization of $77.25 million, a PE ratio of -0.56 and a beta of 1.52. The business has a 50-day moving average of $9.11 and a 200-day moving average of $12.85.

Hedge Funds Weigh In On Enlivex Therapeutics

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its holdings in Enlivex Therapeutics by 99.4% during the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock worth $221,000 after buying an additional 156,336 shares during the last quarter. HRT Financial LP increased its holdings in shares of Enlivex Therapeutics by 719.4% in the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock valued at $108,000 after acquiring an additional 135,198 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after acquiring an additional 67,886 shares during the last quarter. Invesco Ltd. acquired a new stake in shares of Enlivex Therapeutics during the 4th quarter valued at approximately $43,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of Enlivex Therapeutics during the 3rd quarter valued at approximately $57,000. Institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.